734-P: The Effect of Adjunctive Therapy with Liraglutide on Insulin Sensitivity in Overweight Persons with Type 1 Diabetes

Abstract

Type 1 diabetes is associated with an almost threefold higher mortality rate than the general population, primarily driven by excess mortality from cardiovascular disease. Insulin sensitivity evaluated by the estimated glucose disposal rate (eGDR) is a recognized predictor of cardiovascular disease. Here, we evaluated the effect of adjunctive therapy with the glucagon-like peptide 1 receptor agonist (GLP-1RA) liraglutide on eGDR in patients with type 1 diabetes. We calculated eGDR post-hoc in a randomized (1:1) , placebo-controlled, double-blind, clinical trial (NCT01612468) that evaluated the effect of liraglutide 1.8 mg once daily (uptitrated via 0.6 mg and 1.2 mg over 2 weeks) as add-on to insulin treatment compared with placebo in 100 overweight persons with type 1 diabetes (35/65 women/men, age 48 (12) years (mean (standard deviation)) , diabetes duration 23 (12) years, BMI 30 (3) kg/m2, glycated hemoglobin A1c 8.7 (0.7) % / 72 (8) mmol/mol) . After 12 weeks of treatment, liraglutide significantly increased eGDR compared with placebo. However, at end of treatment at week 26, the between-group difference was not statistically significant (Table 1) . These data indicate that liraglutide may improve eGDR, a recognized predictor of cardiovascular disease, in overweight persons with long-standing type 1 diabetes and inadequate glycemic control. Disclosure T.F.Dejgaard: Advisory Panel; Novo Nordisk, Research Support; Novo Nordisk, Speaker's Bureau; AstraZeneca, Boehringer Ingelheim International GmbH, Novo Nordisk. C.S.Frandsen: None. N.Johansen: Employee; Novo Nordisk A/S. S.Madsbad: None. F.K.Knop: Advisory Panel; Boehringer Ingelheim International GmbH, Eli Lilly and Company, Merck Sharp & Dohme Corp., Novo Nordisk, Sanofi, ShouTi, Zucara Therapeutics, Consultant; AstraZeneca, Eli Lilly and Company, Novo Nordisk, Pharmacosmos A/S, Sanofi, ShouTi, Zealand Pharma A/S, Zucara Therapeutics, Research Support; AstraZeneca, Novo Nordisk, Sanofi, Zealand Pharma A/S, Speaker's Bureau; AstraZeneca, Bayer AG, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Novo Nordisk, Sanofi, Stock/Shareholder; Antag Therapeutics. H.U.Andersen: Advisory Panel; Abbott Diabetes, Stock/Shareholder; Novo Nordisk A/S. Funding Supported by an unrestricted grant by Novo Nordisk